B&L Retisert Drug Delivery Implant FDA Filing Delayed By One Year
This article was originally published in The Gray Sheet
Executive SummaryBausch & Lomb will wait for results from its second pivotal trial for the Retisert drug-delivery implant for treating posterior uveitis before submitting a new drug application to FDA, which is expected in mid-2004
You may also be interested in...
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.